دورية أكاديمية
Randomized trials of estrogen-alone and breast cancer incidence: a meta-analysis.
| العنوان: | Randomized trials of estrogen-alone and breast cancer incidence: a meta-analysis. |
|---|---|
| المؤلفون: | Chlebowski RT; The Lundquist Institute, 1124 W. Carson Street, Torrance, CA, USA. rowanchlebowski@gmail.com., Aragaki AK; Fred Hutchinson Cancer Center, Seattle, WA, USA., Pan K; Kaiser Permanente Southern California, Downey, CA, USA., Mortimer JE; City of Hope National Medical Center, Duarte, CA, USA., Johnson KC; University of Tennessee Health Science Center, Memphis, TN, USA., Wactawski-Wende J; University at Buffalo, Buffalo, NY, USA., LeBoff MS; Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA., Lavasani S; City of Hope National Medical Center, Duarte, CA, USA., Lane D; Renaissance School of Medicine, Stony Brook University, Stony Brook, NY, USA., Nelson RA; City of Hope National Medical Center, Duarte, CA, USA., Manson JE; Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. |
| المصدر: | Breast cancer research and treatment [Breast Cancer Res Treat] 2024 Jul; Vol. 206 (1), pp. 177-184. Date of Electronic Publication: 2024 Apr 23. |
| نوع المنشور: | Journal Article; Meta-Analysis |
| اللغة: | English |
| بيانات الدورية: | Publisher: Kluwer Academic Country of Publication: Netherlands NLM ID: 8111104 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-7217 (Electronic) Linking ISSN: 01676806 NLM ISO Abbreviation: Breast Cancer Res Treat Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Dordrecht : Kluwer Academic Original Publication: The Hague ; Boston : M. Nijhoff, c1981- |
| مواضيع طبية MeSH: | Breast Neoplasms*/epidemiology , Randomized Controlled Trials as Topic* , Estrogens*/therapeutic use, Humans ; Female ; Incidence ; Estrogen Replacement Therapy/adverse effects ; Estrogens, Conjugated (USP)/therapeutic use ; Estrogens, Conjugated (USP)/adverse effects ; Estrogens, Conjugated (USP)/administration & dosage |
| مستخلص: | Purpose: In the Women's Health initiative (WHI) randomized clinical trial, conjugated equine estrogen (CEE)-alone significantly reduced breast cancer incidence (P = 0.005). As cohort studies had opposite findings, other randomized clinical trials were identified to conduct a meta-analysis of estrogen-alone influence on breast cancer incidence. Methods: We conducted literature searches on randomized trials and: estrogen, hormone therapy, and breast cancer, and searches from a prior meta-analysis and reviews. In the meta-analysis, for trials with published relative risks (RR) and 95% confidence intervals (CI), each log-RR was multiplied by weight = 1/V, where V = variance of the log-RR, and V was derived from the corresponding 95% CI. For smaller trials with only breast cancer numbers, the corresponding log-RR = (O - E)/weight, where O is the observed case number in the oestrogen-alone group and E the corresponding expected case number, E = nP. Results: Findings from 10 randomized trials included 14,282 participants and 591 incident breast cancers. In 9 smaller trials, with 1.2% (24 of 2029) vs 2.2% (33 of 1514) randomized to estrogen-alone vs placebo (open label, one trial) (RR 0.65 95% CI 0.38-1.11, P = 0.12). For 5 trials evaluating estradiol formulations, RR = 0.63 95% CI 0.34-1.16, P = 0.15. Combining the 10 trials, 3.6% (262 of 7339) vs 4.7% (329 of 6943) randomized to estrogen-alone vs placebo (overall RR 0.77 95% CI 0.65-0.91, P = 0.002). Conclusion: The totality of randomized clinical trial evidence supports a conclusion that estrogen-alone use significantly reduces breast cancer incidence. (© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.) |
| References: | Collaborative Group on Hormonal Factors in Breast C (2019) Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. Lancet 394(10204):1159–1168. Chlebowski RT, Anderson GL, Aragaki AK et al (2020) Association of Menopausal hormone therapy with breast cancer incidence and mortality during long-term follow-up of the Women’s Health Initiative randomized clinical trials. JAMA 324(4):369–380. (PMID: 10.1001/jama.2020.9482327210077388026) The Writing Group for the PEPI Trial (1995) Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 273(3):199–208. Herrington DM, Reboussin DM, Brosnihan KB et al (2000) Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med 343(8):522–529. (PMID: 10.1056/NEJM20000824343080110954759) Viscoli CM, Brass LM, Kernan WN, Sarrel PM, Suissa S, Horwitz RI (2001) A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med 345(17):1243–1249. (PMID: 10.1056/NEJMoa01053411680444) Schierbeck LL, Rejnmark L, Tofteng CL et al (2012) Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ 345:e6409. (PMID: 10.1136/bmj.e640923048011) Cherry N, McNamee R, Heagerty A, Kitchener H, Hannaford P (2014) Long-term safety of unopposed estrogen used by women surviving myocardial infarction: 14-year follow-up of the ESPRIT randomised controlled trial. BJOG 121(6):700–705; discussion 5. Chlebowski RT, Rohan TE, Manson JE et al (2015) Breast cancer after use of estrogen plus progestin and estrogen alone: analyses of data from 2 Women’s Health Initiative randomized clinical trials. JAMA Oncol 1(3):296–305. (PMID: 10.1001/jamaoncol.2015.0494261811746871651) Manson JE, Chlebowski RT, Stefanick ML et al (2013) Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health Initiative randomized trials. JAMA 310(13):1353–1368. (PMID: 10.1001/jama.2013.27804024084921) Gartlehner G, Patel SV, Feltner C et al (2017) Hormone therapy for the primary prevention of chronic conditions in postmenopausal women: evidence report and systematic review for the US preventive services task force. JAMA 318(22):2234–2249. (PMID: 10.1001/jama.2017.1695229234813) Hemminki E, McPherson K (1997) Impact of postmenopausal hormone therapy on cardiovascular events and cancer: pooled data from clinical trials. BMJ 315(7101):149–153. (PMID: 10.1136/bmj.315.7101.14992515442127109) Hodis HN, Mack WJ, Lobo RA et al (2001) Estrogen in the prevention of atherosclerosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 135(11): 939–953. Speroff L, Rowan J, Symons J, Genant H, Wilborn W (1996) The comparative effect on bone density, endometrium, and lipids of continuous hormones as replacement therapy (CHART study) A randomized controlled trial. JAMA 276(17):1397–1403. (PMID: 10.1001/jama.1996.035401700410308892714) Genant HK, Baylink DJ, Gallagher JC, Harris ST, Steiger P, Herber M (1990) Effect of estrone sulfate on postmenopausal bone loss. Obstet Gynecol 76(4):579–584. (PMID: 2170884) Gallagher JC, Kable WT, Goldgar D (1991) Effect of progestin therapy on cortical and trabecular bone: comparison with estrogen. Am J Med 90(2):171–178. (PMID: 10.1016/0002-9343(91)80156-G1847582) Waters DD, Alderman EL, Hsia J et al (2002) Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women: a randomized controlled trial. JAMA 288(19):2432–2440. (PMID: 10.1001/jama.288.19.243212435256) Greenspan SL, Resnick NM, Parker RA (2005) The effect of hormone replacement on physical performance in community-dwelling elderly women. Am J Med 118(11):1232–1239. (PMID: 10.1016/j.amjmed.2005.03.00416271907) Stefanick ML, Anderson GL, Margolis KL et al (2006) Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA 295(14):1647–1657. (PMID: 10.1001/jama.295.14.164716609086) Bradburn MJ, Deeks JJ, Berlin JA, Russell LA (2007) Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events. Stat Med 26(1):53–77. (PMID: 10.1002/sim.252816596572) Sweeting MJ, Sutton AJ, Lambert PC (2004) What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Stat Med 23(9):1351–1375. (PMID: 10.1002/sim.176115116347) Hirji KF, Mehta CR, Patel NR (1987) Computing distributions for exact logistic regression. J Am Stat Assoc 82:1110–1117. (PMID: 10.1080/01621459.1987.10478547) Chlebowski RT, Anderson G, Manson JE et al (2010) Estrogen alone in postmenopausal women and breast cancer detection by means of mammography and breast biopsy. J Clin Oncol 28(16):2690–2697. (PMID: 10.1200/JCO.2009.24.8799204396272881849) Anderson GL, Chlebowski RT, Aragaki AK et al (2012) Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women’s Health Initiative randomised placebo-controlled trial. Lancet Oncol 13(5):476–486. (PMID: 10.1016/S1470-2045(12)70075-X224019133412626) Dauphine C, Moazzez A, Neal JC, Chlebowski RT, Ozao-Choy J (2020) Single hormone receptor-positive breast cancers have distinct characteristics and survival. Ann Surg Oncol 27(12):4687–4694. (PMID: 10.1245/s10434-020-08898-532725527) Fisher B, Costantino JP, Wickerham DL et al (2005) Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 97(22):1652–1662. (PMID: 10.1093/jnci/dji37216288118) Powles TJ, Ashley S, Tidy A, Smith IE, Dowsett M (2007) Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. J Natl Cancer Inst 99(4):283–290. (PMID: 10.1093/jnci/djk05017312305) Veronesi U, Maisonneuve P, Rotmensz N et al (2007) Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy. J Natl Cancer Inst 99(9):727–737. (PMID: 10.1093/jnci/djk15417470740) Cuzick J, Sestak I, Bonanni B et al (2013) Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data. Lancet 381(9880):1827–1834. (PMID: 10.1016/S0140-6736(13)60140-3236394883671272) Cuzick J, Sestak I, Cawthorn S et al (2015) Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial. Lancet Oncol 16(1):67–75. (PMID: 10.1016/S1470-2045(14)71171-4254976944772450) Nelson HD, Fu R, Zakher B, Pappas M, McDonagh M (2019) Medication use for the risk reduction of primary breast cancer in women: updated evidence report and systematic review for the US preventive services task force. JAMA 322(9):868–886. (PMID: 10.1001/jama.2019.578031479143) Chlebowski RT, Aragaki AK (2023) The Women’s Health Initiative randomized trials of menopausal hormone therapy and breast cancer: findings in context. Menopause 30(4):454–461. (PMID: 10.1097/GME.000000000000215436727752) Santen RJ, Stuenkel CA, Yue W (2022) Mechanistic effects of estrogens on breast cancer. Cancer J 28(3):224–240. (PMID: 10.1097/PPO.000000000000059635594470) Jordan VC, Ford LG (2011) Paradoxical clinical effect of estrogen on breast cancer risk: a “new” biology of estrogen-induced apoptosis. Cancer Prev Res (Phila) 4(5):633–637. (PMID: 10.1158/1940-6207.CAPR-11-018521478501) Abderrahman B, Jordan VC (2022) Estrogen for the treatment and prevention of breast cancer: a tale of 2 Karnofsky lectures. Cancer J 28(3):163–168. (PMID: 10.1097/PPO.0000000000000600355944629179096) Santen RJ, Yue W (2019) Cause or prevention of breast cancer with estrogens: analysis from tumor biologic data, growth kinetic model and Women’s Health Initiative study. Climacteric 22(1):3–12. (PMID: 10.1080/13697137.2017.138836430380950) Ellis MJ, Gao F, Dehdashti F et al (2009) Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study. JAMA 302(7):774–780. (PMID: 10.1001/jama.2009.1204196903103460383) Beral V, Reeves G, Bull D, Green J, Million Women Study C (2011) Breast cancer risk in relation to the interval between menopause and starting hormone therapy. J Natl Cancer Inst 103(4):296–305. (PMID: 10.1093/jnci/djq527) Beral V, Peto R, Pirie K, Reeves G (2019) Menopausal hormone therapy and 20-year breast cancer mortality. Lancet 394(10204):1139. (PMID: 10.1016/S0140-6736(19)32033-131474331) Manson JE, Aragaki AK, Rossouw JE et al (2017) Menopausal hormone therapy and long-term all-cause and cause-specific mortality: the Women’s Health Initiative randomized trials. JAMA 318(10):927–938. (PMID: 10.1001/jama.2017.11217288983785728370) Prentice RL, Aragaki AK, Chlebowski RT et al (2021) Randomized trial evaluation of the benefits and risks of menopausal hormone therapy among women 50–59 years of age. Am J Epidemiol 190(3):365–375. (PMID: 10.1093/aje/kwaa21033025002) Goss PE, Ingle JN, Ales-Martinez JE et al (2011) Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med 364(25):2381–2391. (PMID: 10.1056/NEJMoa110350721639806) |
| معلومات مُعتمدة: | R01 CA119171 and R01 CA10921 United States CA NCI NIH HHS; R01 CA119171 and R01 CA10921 United States CA NCI NIH HHS; HHSN268201600018C, HHSN268201600001C National Heart, Lung, and Blood Institute, National Institutes of Health, U.S. Department of Health and Human Services |
| فهرسة مساهمة: | Keywords: Breast cancer incidence; Estrogen-alone; Meta-analysis; Randomized trials |
| المشرفين على المادة: | 0 (Estrogens) 0 (Estrogens, Conjugated (USP)) |
| تواريخ الأحداث: | Date Created: 20240423 Date Completed: 20240617 Latest Revision: 20240617 |
| رمز التحديث: | 20240617 |
| DOI: | 10.1007/s10549-024-07307-9 |
| PMID: | 38653905 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 1573-7217 |
|---|---|
| DOI: | 10.1007/s10549-024-07307-9 |